OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.

類似資料

• The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series
  著者:: Jessica Liu, 等
  出版事項: (2022-01-01)
• LONG-TERM SAFETY PROFILE OF THE ORAL SPLEEN TYROSINE KINASE INHIBITOR FOSTAMATINIB IN IMMUNE THROMBOCYTOPENIA (ITP) AND OTHER DISEASES
  著者:: Q Hill, 等
  出版事項: (2023-10-01)
• Therapy of CF-Patients with Amitriptyline and Placebo - a Randomised, Double-Blind, Placebo-Controlled Phase IIb Multicenter, Cohort-Study
  著者:: Lutz Nährlich, 等
  出版事項: (2013-04-01)
• Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib
  著者:: Vanessa Innao, 等
  出版事項: (2023-01-01)
• Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib
  著者:: Zachary Risch, 等
  出版事項: (2024-05-01)